Compare PGY & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PGY | ABUS |
|---|---|---|
| Founded | 2016 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 888.5M |
| IPO Year | N/A | N/A |
| Metric | PGY | ABUS |
|---|---|---|
| Price | $12.41 | $3.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $34.50 | $5.00 |
| AVG Volume (30 Days) | ★ 5.5M | 2.1M |
| Earning Date | 02-09-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.93 | N/A |
| Revenue | ★ $1,301,360,000.00 | $14,606,000.00 |
| Revenue This Year | $18.57 | $125.30 |
| Revenue Next Year | $14.58 | N/A |
| P/E Ratio | $13.37 | ★ N/A |
| Revenue Growth | 26.07 | ★ 116.64 |
| 52 Week Low | $8.50 | $2.71 |
| 52 Week High | $44.99 | $5.10 |
| Indicator | PGY | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 24.69 | 44.23 |
| Support Level | $12.05 | $3.85 |
| Resistance Level | $15.51 | $4.26 |
| Average True Range (ATR) | 1.34 | 0.30 |
| MACD | -0.72 | 0.01 |
| Stochastic Oscillator | 4.03 | 46.82 |
Pagaya Technologies Ltd is a financial technology company working to reshape the lending marketplace by using machine learning, data analytics, and sophisticated AI-driven credit and analysis technology. It was built to provide a comprehensive solution to enable the credit industry to deliver customers a positive experience while simultaneously enhancing the broader credit ecosystem. Its proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit. The company generates majority of its revenue from United States.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.